University of Michigan medical school to drop funding from drug, device companies
Starting next year, the University of Michigan's medical school will become the first to refuse funding for its continuing education courses for doctors from drug and device makers, the New York Times reported.
The move was made to reduce bias of outside interests from the presentation of medical information. The decision to drop commercial financing for postgraduate medical education could mean as much as a $1 million drop in financing at U-M, according to the story.
Earlier this year, U-M medical school officials said they planned to review and improve the medical school's conflict-of-interest policies in the wake of increasing criticism of policies at schools across the U.S.
Last year, a government report found the policies at most of the nation’s universities were too weak, relying on researchers to self-disclose any potential financial conflicts of interest from consulting jobs or relationships with drug and device companies.
Ray Hutchinson, the associate dean for regulatory affairs at the University of Michigan's Medical School, said continuing medical education, speakers’ bureaus where physicians in the field take money for giving information from drug or device makers, as well as other relationships between faculty and industry, were being reviewed.